EUCTR2016-001121-14-IT进行中（未招募）1 期
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 331
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, consistent with Chapel-Hill Consensus
- •Conference definitions
- •2. Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with cyclophosphamide or rituximab is needed; where
- •approved, adolescents (12-17 year old) may be enrolled
- •3. Positive test for anti-PR3 or anti-MPO (current or historic) antibodies
- •4. At least one major item, or at least 3 minor items, or at least the 2 renal items of proteinuria and hematuria in the BVAS
- •5. Estimated glomerular filtration rate =15 mL/minute/1.73 m2 (using the MDRD method) at screening
- •6. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; written Informed Consent should
- •be obtained from the legal guardian in accordance with regional laws or regulations for patients 12 to 17 years of age
- •7. Judged by the Investigator to be fit for the study, based on medical history, physical examination (including electrocardiogram [ECG]), and
- •clinical laboratory assessments.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Pregnant or breast-feeding
- •2. Alveolar hemorrhage requiring invasive pulmonary ventilation support
- •anticipated to last beyond the screening period of the study
- •3. Any other known multi-system autoimmune disease including eosinophilic granulomatosis with polyangiitis (Churg-Strauss), systemic
- •lupus erythematosus, IgA vasculitis (Henoch-Schönlein), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane
- •disease, or cryoglobulinemic vasculitis
- •4. Required dialysis or plasma exchange within 12 weeks prior to screening
- •5. Have had a kidney transplant
- •6. Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil, or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the
- •cyclophosphamide or rituximab dose on Day 1
- •7. Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 weeks prior to screening
- •8. Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior
- •to the screening visit
- •9. Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x109/L); received anti-TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening
- •10. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as carbamazepine, phenobarbital, phenytoin, rifampin, or St. John's wort
- •11. Any of the following within 12 weeks prior to screening: symptomatic congestive heart failure requiring prescription medication, unstable angina (unless successfully treated with stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or stroke
- •12. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ such as cervical or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
研究者
相似试验
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer - N/Aadvanced, unresectable, or metastatic (stage IIIB or IV) nonsquamous non-small cell lung cancerEUCTR2006-005306-31-BEEli Lilly and Company limited120
进行中（未招募）
1 期
Study to Evaluate the Long-Term Safety and Efficacy of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Heterozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850Heterozygous Familial HypercholesterolemiaEUCTR2020-004390-44-ESIB Therapeutics, LLC600
进行中（未招募）
1 期
A Study of Ramucirumab (LY3009806) and best supportive care in Participants with Hepatic CancerMedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2014-005068-13-PLEli Lilly and Company279
进行中（未招募）
1 期
Study of VE202 in Patients with Mild-to-Moderate Ulcerative ColitisEUCTR2021-001280-24-LTVedanta Biosciences, Inc.100
招募中
2 期
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis2024-512558-40-00Vedanta Biosciences Inc.74